Quantum Genomics (PAR: ALQGC)

Last close As at 05/08/2026

0.00 (0.00%)

Market capitalisation

Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. The Phase IIb study in hypertension was recently very positive and the Phase IIb in heart failure should start in Q219.

Latest Insights

View More

Healthcare | Flash note

Quantum Genomics — Firibastat misses endpoints in Phase III

Healthcare | Initiation

Quantum Genomics — A fresh take on cardiovascular medicine

Healthcare | Update

Quantum Genomics — Phase IIb QUORUM results

Market Data

Share Price
Market Cap
52-Week High
52-Week Low
% Change 1M
% Change 6M
% Change 12M
Ave. Daily Volume 1yr

Thematics

thematic

Industrials

Edison explains: Europe’s ageing buildings

thematic

Consumer

Stock of the month – PZ Cussons

thematic

Edison explains: The return of gold M&A

thematic

The new retail investors: A portrait

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.